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Gene therapy with interleukin-10 receptor and interleukin-12
induces a protective interferon-c-dependent response against
B16F10-Nex2 melanoma
LHL Marchi, T Paschoalin, LR Travassos and EG Rodrigues
Experimental Oncology Unit, Department of Microbiology, Immunology and Parasitology, Universidade
Federal de Sa˜o Paulo-Escola Paulista de Medicina, Sa˜o Paulo, Brazil
Antitumor immune responses are associated with proinflammatory cytokines, whereas tumor-developing animals generally have
increased the production of immunosuppressive cytokines. Here, we show that splenocytes from C57Bl/6 mice resistant to low doses
of B16F10-Nex2 melanoma cells produced twofold or higher interferon-g (IFN-g)/interleukin-10 (IL-10) ratios, whereas cells from
tumor-bearing animals produced predominantly IL-10. IL-10-knockout (IL-10KO) mice were significantly more resistant to B16F10-
Nex2 development, producing increased amounts of IL-12 and IFN-g. To neutralize IL-10 in vivo, aiming at cancer therapy,
recombinant eukaryotic plasmid expressing the soluble extracellular region of the murine IL-10 receptor a-chain was constructed
(pcDNA3-sIL-10R). Plasmid-treated melanoma-challenged animals showed extended survival time, the protective response was IFN-g
dependent and enhanced by co-immunization with a plasmid expressing IL-12. Dendritic cells (DCs) from IL-10KOmice, primed with
B16F10-Nex2 antigens (TAg), secreted increased amounts of T-helper 1-type cytokines and increased the expression of surface
activation markers. Vaccination of C57Bl/6 mice with TAg-activated IL-10KO DCs, as well as with TAg-primed DCs from C57Bl/6
mice transfected with pcDNA3-sIL10R plasmid, significantly increased animal survival. In conclusion, an IFN-g-dependent protective
response was induced against B16F10-Nex2 cells by neutralization of IL-10 with pcDNA3-sIL10R plasmid. This effect was enhanced
by association with IL-12 gene therapy (80% protection), and could be mediated by TAg-primed DCs.
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Introduction
Most of the diverse nonspecific and specific antitumor
approaches that stimulate the immune system, aiming at a
protective response and destruction of tumor cells, have
shown limited clinical efficacy so far. Failures in cancer
treatment can be explained, at least in part, by tumor-
induced immune suppression. A large number of cyto-
kines, hormones and other molecules secreted by tumors
and by local recruited immune cells were shown to have
immunomodulating properties. A frequently studied
immune response is the increased production of type-2
cytokines that is associated with tumor development in
tumor-bearing animals and cancer patients.1–4
Early effectors of antitumor immunosurveillance must
perform the critical tasks of producing interferon-g
(IFN-g) and killing the target cells.5 A significant number
of reports on models of primary tumor formation give
support to these requirements. Relevant cellular sources
of IFN-g in the immunosurveillance include the gd-T cells
that were shown to play an important role in developing a
protective antitumor response.6 IFN-g promotes the
generation of tumor-specific CD4þ T-helper 1-type
(Th1) T cells and cytolytic T cells, as well as the activation
of macrophages with cytocidal activity, thus fostering an
antitumor response mediated by adaptive and innate
immunity.7 Furthermore, IFN-g upregulates tumor im-
munogenicity, which may explain tumor detection and
elimination in immunocompetent hosts.5 Accumulation
of IFN-g, as in IFN-g-receptor knockout mice, also leads
to resistance to syngeneic tumor implants that express
IFN-g receptor owing to a direct antitumor effect of the
cytokine.8 Also in support of the protective role of IFN-g
in cancer development, 17 out of 25 significantly altered
genes in T and B cells from melanoma patients were IFN-
stimulated genes, indicating that defects in IFN signaling
are dominant mechanisms of immune dysfunction in
cancer patients.9 Defects in lymphocyte IFN signaling
were also observed in human breast and gastrointestinal
cancers.10
Cancer immunosurveillance can eliminate a significant
number of transformed cells. In experimental models, the
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subcutaneous implantation of a limited number of tumor
cells may result in tumor-resistant animals. Using B16F10
murine melanoma cells, we observed that the low
percentage of tumor-resistant mice (2–3%) always showed
a twofold or higher ratio of IFN-g/interleukin-10 (IL-10),
whereas tumor-developing animals had inverse ratios,
with IL-10 being the predominant cytokine. The opposing
effects of these cytokines are directly related to the cells
producing them and their numbers. An appropriate
example is that of tumor-infiltrating T lymphocytes. The
presence of IFN-g-producing CD8þ T cells and CD4þ
helper T cells is beneficial to combat the tumor, whereas that
of IL-10- and transforming growth factor-b- (TGF-b) pro-
ducing CD4þCD25þ and CD8þ Treg is detrimental.11,12
Using a model of colon carcinoma cells (CT26), it was
shown that in vitro neutralization of anti-TGF-b and IL-10
enhanced CTL responses against the tumor cells. In vivo,
depletion of CD4þ T cells increased IFN-g production by
CD8þ T cells and delayed tumor development.12
In a study of metastatic melanoma patients, it was
observed that plasma concentrations of type-2 cytokines,
IL-4, IL-5, IL-10 and IL-13, in tumor-bearing patients
were significantly higher than those with resected
melanomas.13 High numbers of CD4þCD25highFoxp3þ
regulatory T lymphocytes secreting IL-10 and TGF-b
were described in lymph nodes of metastatic patients.14
Experimentally, during tumor progression, the number of
IL-10-secreting CD4þ T cells and NK cells increased in
the spleens of mice inoculated subcutaneously with
B16F10 melanoma cells, whereas the number of IFN-g-
secreting CD4þ T lymphocytes and NK cells declined
dramatically.15 IL-10 is a pleiotropic cytokine secreted by
B lymphocytes, eosinophils, mast cells, macrophages,
dendritic cells (DCs), NK cells and several subsets of
T lymphocytes, such as CD8þ , CD25þFoxp3þ and
antigen-driven regulatory CD4þ T cells. This interleukin
acts as a regulator of the protective inflammatory
response in several infections, but if it is overexpressed,
it plays the role of an immunosuppressive cytokine,
inhibiting proinflammatory cytokine production, the
expression of co-stimulatory molecules and major histo-
compatibility complex (MHC) class II antigens, as well as
the general antigen-presenting function of macrophages
and DCs (reviewed in O’Garra et al.16).
In this study, we show that the susceptibility of C57Bl/6
mice to B16F10 melanoma is associated with increased
production of IL-10 by immune cells, and that the
neutralization of this cytokine by gene therapy increased
tumor rejection in vivo. This protective response was
increased by the association with IL-12-expressing plas-
mid, and adoptive transfer of ex vivo tumor-activated and
IL-10-neutralized DCs induced a significant protective res-
ponse in mice challenged with B16F10-Nex2 melanoma cells.
Materials and methods
Animals
Inbred male C57Bl/6 (wild-type: WT) mice, 6–8 weeks
old, were purchased from CEDEME (Centro de
Desenvolvimento de Modelos Experimentais, UNIFESP,
Sa˜o Paulo, Brazil). IL-10 genetically deficient (IL-10-
knockout: IL-10KO) mice were housed and bred in
specific pathogen-free conditions at the Cell Biology
Animal Facility (UNIFESP). In all experiments, age-
paired animals were used, and IL-10KO animals were
treated before and during experiments with 0.04%
benzoilmetronidazol on drinking water due to natural
colitis development.17
Tumor cell line and cell culture conditions
B16F10-Nex2 is a subline from B16F10 murine melano-
ma cell line,18 isolated at the Experimental Oncology Unit
(UNONEX, Sa˜o Paulo, Brazil) and characterized by low
immunogenicity and moderate aggressiveness.19 Cells
were maintained in RPMI-1640 medium (pH 7.2),
supplemented with 10% heat-inactivated fetal calf serum,
10mM Hepes (N-2-hydroxyethylpiperazine-N0-2-ethane-
sulfonic acid) and 24mM NaHCO3 (all from GIBCO,
Minneapolis, MN), and 40mgml1 gentamycin sulfate
(Hipolabor Farmaceˆutica, Minas Gerais, Brazil).
Preparation of B16F10-Nex2 cell lysate
A suspension (5 106 cells per ml) of in vitro cultured
B16F10-Nex2 cells was lysed by sonication at 40Hz (five
cycles of 12 s, sample maintained on ice) and the efficiency
of the method was checked by light microscopy. The
sonicated cell suspension was g-irradiated (600 rads) for
sterilization. Aliquots were kept at 80 1C.
pcDNA3—sIL-10R construction
To construct the eukaryotic expression vector of the
soluble extracellular portion of the murine IL-10 receptor
(sIL-10R), the sequence corresponding to this domain
(amino acids 1–189) was cloned from lipopolysaccharide-
activated macrophages. Briefly, bone marrow-derived
murine macrophages were stimulated for 30 h with
200 ngml1 of lipopolysaccharide, and RNA extractions
were carried out using Trizol reagent (Invitrogen, Sa˜o
Paulo, Brazil), following the manufacturer’s instructions.
In order to improve reverse transcription-polymerase
chain reaction (RT-PCR) amplification, a preliminary
gene-specific cDNA synthesis using ‘Thermo Script
RT-PCR System’ (Invitrogen) and a 30 murine IL-10R-
specific primer (reverse, 50-TGGAGCCTGGCTAGCTG
GTCACAGTAGGTCT-30; Ho et al.20) was carried out.
This specific cDNA was then used as template for PCR
amplification of sIL-10R using forward (50-ATGTTGTC
GCGTTTGCTCCC-30) and reverse (50-CCTGTTTCAC
TCTCTTGGTTG-30) primers. A PCR product of 560 bp
was purified using ‘Bioclean for Purification of DNA
Bands’ (Biotools, Sa˜o Paulo, Brazil) and cloned into a
pGEM-T vector (Promega, Madison, WI). The insert was
automatically sequenced using as primers the sequences
corresponding to T7 (sense) and SP6 (antisense) vector
promoters, and the sequence compared with those
available in the NCBI GenBank (ID 16154). Nucleotide
sequencing was carried out at the Human Genome
Research Center, Sa˜o Paulo University (USP). The insert
was then subcloned into a NotI restriction site of a
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pcDNA3 vector (Invitrogen), which was used to trans-
form Escherichia coli DH5a-competent cells by heat
shock. Plasmids from a selected clone were purified in
CsCl gradient with ethidium bromide after ultracentrifu-
gation at 500 000 g for 16 h (Beckman, Coulter, CA, VTi
90 rotor), followed by washing with saturated butanol to
remove the ethidium bromide. Plasmids were precipitated
with ethanol 100% for 16 h, washed twice with ethanol
70%, then re-suspended in sterile phosphate-buffered
saline (PBS) and stocked at 20 1C.
Analysis of sIL-10R expression by transfected cells
B16F10-Nex2 cells were transfected with pcDNA3-
sIL10R plasmid using DOTAP reagent, following the
manufacturer’s instructions (Roche Applied Science,
Indianapolis, IN). G418-resistant cells were selected and
expanded in vitro. The sIL-10R mRNA was detected by
RT-PCR using the same primers previously used for gene
cloning. Primers for b-actin were used as control
(forward, 50-CAGAGCAAGAGAGGGATCCTGA-30;
reverse, 50-TGATCCACATCTGCTGGAAGGT-30). For
intracellular detection of the expressed recombinant
protein, transfected cells were permeabilized with PBS
containing saponin 0.05%, after pretreatment for 20min
with PBS containing 0.05% saponin and 1% paraformal-
dehyde. Permeabilized cells were incubated during 1 h
with phycoerythrin-conjugated anti-mouse murine IL-10R
monoclonal antibody (mAb) (CD210, clone 1B1.3a; BD
Pharmingen, San Jose, CA), fixed with 2% paraformal-
dehyde in PBS and fluorescence was measured in a
FACSCalibur flow cytometer (BD Biosciences, San Jose,
CA). Data were collected for 10 000 viable cells and
analyzed using the CellQuestPro software (Becton
Dickinson, San Jose, CA).
Immunoprecipitation detection of sIL-10R in culture
supernatants
The secretion of the transgenic molecule was verified by
immunoprecipitation. Transfected B16F10-Nex2 cell cul-
ture supernatant was incubated with murine mAb anti-
IL-10R (BD Pharmingen) in RIPA (radio immunopreci-
pitation assay) buffer (1.5M NaCl, 0.5M Tris, 10% NP40
at pH 7.5) for 16 h at 4 1C. Protein A-Sepharose beads
(Sigma Aldrich, Saint Louis, MO) were added and the
suspension was further incubated for 4 h at 4 1C. After
centrifugation, beads were washed three times in RIPA
buffer. Proteins were eluted by the addition of sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer and by heating the sample at 95 1C
for 3min. Samples were analyzed by standard 12.5%
polyacrylamide gel electrophoresis (SDS-PAGE). Sepa-
rated proteins were then transferred to nitrocellulose
membranes (100V, 1 h), and membranes were stained
with Ponceau-S solution (0.1% Ponceau in 10% acetic
acid) to check the efficiency of the method. Every step was
followed by several washings with PBS–0.05% Tween.20
Membranes were blocked with PBS containing 5% skim
milk (PBS–milk 5%) for 2 h at room temperature. Anti-
IL-10R (BD Pharmingen) was diluted 1:500 in PBS-1%
skim milk and incubated for 16 h at 4 1C, following
incubation with anti-rat streptavidin-peroxidase-conju-
gated immunoglobulin G (Sigma Aldrich) diluted 1:1000
in PBS–1% skim milk for 1 h at 37 1C. Detection was
performed with Immobilon Western Substrate (Millipore,
Sa˜o Paulo, Brazil) diluted 1:5 in PBS and membranes
were exposed to X-ray film (Kodak, Sa˜o Paulo, Brazil)
for 15min.
Macrophage and DC maturation from murine bone
marrow progenitors
Primary cultures of DCs were obtained from C57Bl/6 or
IL-10KO bone marrow progenitors as described pre-
viously.21 Briefly, bone marrow cells were collected and
cultured ex vivo in RPMI-1640 medium (pH 7.2),
supplemented with 10% fetal calf serum, 50 mM 2-
mercaptoethanol, 100nM amino acids supplement (GIBCO),
30 ngml1 of granulocyte–macrophage colony-stimulat-
ing factor and 10 ngml1 of IL-4 (both from Peprotech,
Colonia Banjidal, DF, Mexico). Culture medium was
replaced with fresh medium on day 4, and non-adherent
cells were harvested and used as bone marrow-derived
DCs on day 7. Macrophages were obtained from bone
marrow precursors by culturing the cells in RPMI-1640
medium supplemented with 20% fetal calf serum and
30% L929 cell-conditioned medium as described pre-
viously.22 Culture medium was replaced with fresh
medium on day 4, and adherent cells were harvested
and used as bone marrow-derived macrophages on day 7.
Fluorescence-activated cell sorting
For the detection of surface activation markers, bone
marrow-derived DCs from C57Bl/6 or IL-10KO mice
were cultured at 5 105 cells per well, in 12-well plates,
for 24 h in the presence of 100Uml1 of murine IFN-g
(Peprotech) and the B16F10-Nex2 cell lysate (equivalent
to 104 cells per well). Cells were harvested and stained
with phycoerythrin- or fluorescein isothiocyanate-conju-
gated anti-MHC class II, anti-CD40, anti-CD80 or anti-
CD86 antibodies (BD Pharmingen) for 1 h on ice, and
then fixed with 2% paraformaldehyde in PBS. Fluores-
cence was measured in a FACSCalibur flow cytometer
(BD Biosciences). Data were collected for 10 000 viable
cells and analyzed using the CellQuestPro software
(Becton Dickinson). For intracellular IFN-g and IL-10
quantification, 104 B16F10-Nex2 cells were subcuta-
neously inoculated in mice and after 25 days splenocytes
were harvested. Erythrocytes were lysed (0.1M NH4Cl,
pH 7.2) and 4 106 cells per ml were stimulated ex vivo
for 8 h with phorbol myristate acetate (PMA) (10 ngml1)
and ionomycin (3mM). After washing with PBS contain-
ing 1% bovine serum albumin, 106 cells per sample were
treated with PBS, 0.05% saponin, 1% formaldehyde for
20min and for 10min with PBS/0.05% saponin (permea-
bilization buffer). Intracellular staining of cytokines was
performed for 1h with biotinylated anti-IFN-g or anti-IL-10
(Pharmingen) 1:100, diluted in permeabilization buffer.
After PBS washing, cells were incubated with phycoery-
thrin-conjugated streptavidin (BD Pharmingen) 1:200,
diluted in permeabilization buffer and fixed in PBS/2%
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formaldehyde. Fluorescence was measured as described
above.
Cytokine quantification in culture supernatants and sera
by enzyme-linked immunosorbent assay
Splenocytes obtained as described above (106 cells per
well) were cultured for 3 days in 96-well plates in the
presence of 10 ngml1 PMA and 3mM ionomycin, or
B16F10-Nex2 cell lysate (equivalent to 105 tumor cells per
well). Cytokines (IFN-g, IL-2, IL-4, IL-6, IL-10 and
IL-12) were quantified in culture supernatant. Bone
marrow-derived macrophages or DCs from C57Bl/6 or
IL-10KO mice (5 105 cells per well) were cultured in
12-well plates for 3 days in the presence of 100Uml1
murine IFN-g and B16F10-Nex2 cell lysate (equivalent to
104 tumor cells per well). Cytokines (IFN-g, IL-12 and
tumor necrosis factor-a: TNF-a) were quantified in
culture supernatants. Sera from C57Bl/6 or IL-10KO
mice subcutaneously challenged with 5 104 B16F10-
Nex2 cells were collected 11 days after tumor cell
injection, and IFN-g was quantified in pooled samples
of five animals, 1:10 diluted. Cytokine quantifications
were performed using sandwich enzyme-linked immuno-
sorbent assay (ELISA) kits (Peprotech) following the
manufacturer’s instructions.
Tumor challenge and in vivo protocols
Different numbers of B16F10-Nex2 cells were inoculated
subcutaneously in the right flank and tumor evolution
was monitored every 2 days using a caliper. The
maximum tumor volume allowed (calculated using the
formula V¼ 0.52D12D2, where D1 and D2 are the
short and long diameters, respectively) was 3 cm3. All
animal experiments were approved by the Animal Ethics
Committee at UNIFESP (protocol number 1133/8).
For gene therapy, two different plasmids were used, the
pcDNA3-sIL-10R and a plasmid expressing both p35 and
p40 subunits of murine IL-12 under the CMV promoter
(pIL-12), provided by Alexander Rakhmilevich from the
University of Wisconsin.23 A vector containing luciferase
cDNA under the CMV promoter (pCMV, Hebeler-
Barbosa et al.24) and an empty pcDNA3 plasmid were
used as negative controls. Viable tumor cells were
inoculated subcutaneously on day 0, and 100 mg of
pcDNA3-sIL-10R or the empty plasmid pcDNA3 (con-
trol) were injected intradermally on days 1, 8 and 15, at
the tail base. A single injection of 100mg of pIL-12 or the
control pCMV was injected on day 1. In vivo IFN-g
depletion was performed using a purified anti-murine
IFN-g (XMG1.2 clone) provided by Dr Joa˜o S Silva,
School of Medicine, USP at Ribeira˜o Preto, Brazil. Mice
were injected intraperitoneally with 250 mg of the mAb on
day 1, and with 125 mg on days 1, 3, 5, 7, 9 and 11. In a
vaccination protocol, animals were adoptively transferred
with IL-10KO or C57Bl/6 bone marrow-derived DCs.
These cells were admixed or not with B16F10-Nex2 cell
lysate (equivalent to 5 103 B16F10-Nex2 cells), and
injected subcutaneously (4 104 cells) 2 weeks and 1 week
before the tumor challenge. Alternatively, sIL-10R-
transfected DCs were used. For transfection, 107 C57Bl/6
bone marrow-derived DCs were incubated with pcDNA3
or pcDNA3-sIL-10R and DOTAP reagent (Roche Ap-
plied Science) for 12 h. After antibiotic selection for 3 days
(G418, 300 ngml1; Gibco BRL Life Technologies,
Hayward, CA), transfected DCs were associated with
tumor cell lysate (as described above) and inoculated
subcutaneously on days 4 and þ 3 of tumor challenge.
The tumor challenge was carried out subcutaneously with
104 or 5 104 viable B16F10-Nex2 cells, in the same flank
used for DCs inoculation.
Statistical analysis
Data are represented as means±standard errors.
Student’s t-test was used to analyze all in vitro experi-
ments, and Kaplan-Meier log-rank test was used to
analyze in vivo experiments. In both tests, the differences
were considered statistically significant when Po0.05.
Results
Susceptibility to B16F10-Nex2 murine melanoma cells
is associated with increased IL-10 produced by
splenocytes
When C57Bl/6 mice are injected subcutaneously with
syngeneic melanoma B16F10-Nex2 cells, we consistently
observed a low percentage of mice that do not develop
tumors, and this effect was inversely correlated with the
number of inoculated cells (data not shown). In order to
verify the cytokine profile in these tumor inoculated mice,
we injected subcutaneously a low dose of B16F10-Nex2
cells in male C57Bl/6 mice, and the resistant animals were
selected to receive a higher subcutaneous dose 60 days
later, in the contrary flank. Tumor-bearing (1.5 cm3
tumors) and tumor-resistant animals after the second
challenge were analyzed for representative anti- and
proinflammatory cytokine production by ex vivo tumor-
stimulated splenocytes, 30 days after the second tumor
cell injection. Cells from tumor-free mice displayed a
strong tumor-specific IFN-g production and smaller
amounts of IL-6 and IL-10, suggesting the induction of
a predominant protective T-helper 1-type (Th1) response.
In contrast, tumor-bearing mice showed a tumor-specific
IL-10 predominant response with lower IFN-g produc-
tion (Figure 1a). The same pattern was observed when
splenocytes from these animals were nonspecifically
stimulated ex vivo and the intracellular contents of IFN-
g and IL-10 were measured. The ratio of IFN-g- to IL-10-
producing cells was always higher in tumor-free than in
tumor-bearing mice (Figure 1b).
We concluded that B16F10-Nex2 melanoma development
is correlated with the increased production of IL-10, and
that inhibition of tumor development is associated with the
induction of a protective tumor-specific Th1-type response,
represented by twofold or higher IFN-g/IL-10 ratio.
Increased survival of IL-10KO mice after B16F10-Nex2
cell implantation depends on IL-12 and IFN-g
We then analyzed tumor development in the absence of
IL-10, using genetically deficient mice. After subcutaneous
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inoculation of tumor cells in IL-10 genetically deficient
(IL-10KO) and WT C57Bl/6 mice, we observed that IL-
10KO mice survived significantly longer than C57Bl/6
animals (Figure 2). B16F10-Nex2 melanoma cells did not
secrete IL-10 in vitro, and neither the cell growth required
this cytokine (data not shown).
As inhibition of tumor development in C57Bl/6 mice
was correlated with increased amounts of IFN-g, we
investigated IL-12 and IFN-g production in IL-10KO-
resistant and WT-susceptible animals.
Tumor-free IL-10KO mice showed a 10-fold increased
level of IFN-g in serum compared with tumor-bearing
C57Bl/6 animals (Figure 3a). Splenocytes from tumor-free
IL-10KO mice produced higher levels of IL-12 than cells
from tumor-bearing C57Bl/6 mice after ex vivo stimula-
tion with tumor cell lysate, as measured by ELISA of
culture supernatants (Figure 3b).
Figure 2 Survival of IL-10 genetically deficient (IL-10KO) and wild-
type C57Bl/6 mice inoculated subcutaneously with B16F10-Nex2
melanoma cells. IL-10KO and C57Bl/6 mice were inoculated
subcutaneously with (a) 5 103, (b) 5 104 and (c) 5105 viable
B16F10-Nex2 cells. Representative results of at least three
independent experiments are shown. (a) Six animals per group,
Po0.001. (b) Seven animals in the C57Bl/6 and eight in the IL-10KO
group, Po0.01. (c) Seven animals in C57Bl/6 and six in the IL-10KO
group, Po0.002.
Figure 1 Cytokine profile in tumor-bearing and tumor-free C57Bl/6
mice. (a) C57Bl/6 mice were inoculated subcutaneously with 5103
tumor cells, and tumor-free animals were re-inoculated 60 days later
with 5104 tumor cells. At 30 days after the second tumor cell
inoculation, animals bearing 1.5 cm3 tumors (Tbear) and tumor-free
(Tfree) mice were selected. Splenocytes were stimulated (B16) or
not (NS) with a B16F10-Nex2 cell lysate. Cytokines were measured
in culture supernatants by ELISA. *Po0.01, comparing cytokine
levels in both mice. (b) C57Bl/6 mice were inoculated subcuta-
neously with 104 B16F10-Nex2 cells. Splenocytes from Tfree or
Tbear (with 3 cm3 maximal tumor volume) were stimulated ex vivo
and the intracellular production of IFN-g and IL-10 was measured as
described in Material and methods. The absolute number of cells
was used to calculate the ratio. Bars represent different animals.
Results are representative of at least five independent experiments.
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Although the majority of IL-10KO mice inoculated
with low numbers of tumor cells was protected, some
animals developed subcutaneous tumor. Splenocytes from
tumor-free IL-10KO mice produced increased amounts of
IL-12 and IFN-g as compared with tumor-bearing
animals when tumor antigens were used for stimulation
ex vivo. When a nonspecific stimulus was used (PMA and
ionomycin), cells from both animals produced the same
amount of IFN-g. The IL-12 production, however, was
compromised in tumor-bearing animals (Figure 3c).
IFN-g has a pivotal role in the inhibition of tumor
development in the absence of IL-10, as shown after
neutralization of this cytokine in vivo by anti-IFN-g mAb.
IFN-g-depleted IL-10KO animals showed reduced survi-
val, similar to that in WT C57Bl/6 animals (Figure 3d).
Results suggest, therefore, that the absence of IL-10
increased the IFN-g-dependent protective antimelanoma
response. They also suggest that IL-10 neutralization may
be beneficial to the tumor-bearing host.
Construction of a vector expressing the soluble
extracellular domain of IL-10R
In vivo neutralization of IL-10 was obtained in several
systems with monoclonal antibodies directed to the
receptor of this cytokine.25–27 We tested a new approach
for cytokine neutralization, vaccinating mice with a
plasmid expressing the extracellular portion of the murine
IL-10R as a soluble decoy protein in vivo.
Using RNA from lipopolysaccharide-stimulated
macrophages, we cloned the cDNA fragment correspond-
ing to the hydrophilic N-terminal portion of murine
IL-10R a-chain, mature protein and its signal peptide,
comprising the extracellular region of the receptor, named
here sIL-10R (Figure 4a). This encoding sequence was
inserted in an eukaryotic expression plasmid (pcDNA3)
and the construction pcDNA3-sIL-10R was tested in vitro
and in vivo.
No base pair exchange, deletion or inclusion was
detected by nucleotide sequencing of the construction
(data not shown).
B16F10-Nex2 cells were transfected with the plasmid
and sIL-10R mRNA was detected by RT-PCR using the
same primers used for gene cloning (Figure 4b). Intracel-
lular staining with an mAb directed to the murine IL-10R
(CD210) showed sIL-10R protein expression by these cells
(Figure 4c). More importantly, the recombinant protein
was secreted by the transfected cells as a group of three
species between 30 and 45 kDa, detected by immunopre-
cipitation and immunoblotting with the anti-CD210 mAb
(Figure 4d). On the basis of the amino-acid sequence of
the expressed protein fragment, the predicted molecular
weight was 22 kDa. As shown, however, for human
IL-10R, the occurrence of more than one species may be
explained by different N-glycosylated fragments in the
sample. Tan et al.28 examined the extracellular portion of
human IL-10R resolved as three species, and identified
five possible N-glycosylation sites in the peptide sequence.
The human recombinant protein was restored to the
predicted molecular weight upon enzymatic deglycosyla-
tion, proving that the altered migration in electrophoresis
Figure 3 Cytokine profile of tumor-injected IL-10KO mice. (a)
C57Bl/6 and IL-10KO mice were injected subcutaneously with
B16F10-Nex2 cells and IFN-g was measured in pooled serum
samples from five animals as described in Materials and methods,
Po0.001. (b) IL-10KO and C57Bl/6 mice were inoculated sub-
cutaneously with 103 B16F10-Nex2 cells, and after 7 days, 104 tumor
cells were re-inoculated contralaterally. Splenocytes were collected
after 20 days and stimulated with B16F10-Nex2 cell lysate for 48 h.
IL-12 concentration in culture supernatant was measured by ELISA.
Individual values with standard deviations are shown. Black lines
represent the means for each group, Po0.001. (c) IL-10KO mice
were inoculated with 104 tumor cells, and splenocytes from tumor-
free (Tfree) or tumor-bearing mice (Tbear) were stimulated with a
lysate of B16F10-Nex2 cells (solid bars) or PMA and ionomycin
(empty bars). Cytokine concentrations in culture supernatants were
measured by ELISA, *Po0.03. (d) Survival plots for WT, IL-10KO
and IFN-g-depleted IL-10KO mice after subcutaneous inoculation of
104 B16F10-Nex2 cells. IFN-g in vivo was depleted as described in
Materials and methods. Representative results of two independent
experiments using 10 animals per group are shown, Po0.02,
comparing IFN-g-depleted and -non-depleted IL-10KO groups.
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was owing to N-linked sugar residues. The murine IL-10R
protein also contains five putative N-glycosylation sites,
as predicted in the software NetNGlyc, developed by the
Center for Biological Sequence Analysis of Technical
University of Denmark (http://www.cbs.dtu.dk/services/
NetNGlyc/). Four putative sites are located at the
extracellular domain, at amino-acid residues 50–54,
66–69, 113–116 and 182–185.
In vivo IL-10 neutralization by gene therapy induced an
IFN-g-dependent protective antimelanoma response,
and this response was enhanced by IL-12-expressing
plasmid
C57Bl/6 mice subcutaneously challenged with B16F10-
Nex2 cells and treated with subcutaneous pcDNA3-sIL-
10R injections showed significantly increased survival,
similar to PBS-treated IL-10KO animals. Control groups,
treated with PBS or pcDNA3 empty plasmid, showed
reduced survival (Figure 5a).
Neutralization of IFN-g in pcDNA3-sIL-10R-treated
animals abolished the protective effect, indicating that the
protection induced by IL-10 neutralization in vivo by gene
therapy depended on IFN-g (Figure 5b).
On trying to improve the tumor-protective Th1-type
response obtained with sIL-10R gene therapy, C57Bl/6
mice were treated concomitantly with a single dose of a
plasmid expressing functional murine IL-12 (pCMV-
IL12), as described previously.24 Animals treated with
empty plasmids were not protected, showing subcuta-
neous nodules before the 30th day after tumor cell
inoculation, and animals treated with pcDNA3-sIL10R
or pCMV-IL12 were partially protected. Treatment using
a combination of both plasmids rendered a higher number
of tumor-free animals 50 days after tumor cell inoculation
(Figure 5c).
These results showed that the plasmid containing a
minigene encoding the extracellular domain of the murine
IL-10R expressed the peptide in vivo, and that neutraliza-
tion of IL-10 increased survival of B16F10-Nex2 tumor-
bearing mice. The association of IL-12 immunotherapy
with IL-10 neutralization induced a stronger protective
antitumor immune response.
Characterization of mechanisms involved in the
protective immune response induced in the absence
of IL-10
To further characterize the immunological mechanisms
that could be involved in the protective antimelanoma
response observed in the absence of IL-10, we investigated
the cytokine production and the activation level of bone
marrow-derived macrophages and DCs from C57Bl/6 and
IL-10KO animals, stimulated in vitro with IFN-g and
B16F10-Nex2 cell lysate.
In these conditions, IL-10KO macrophages produced
more IFN-g, IL-12 and TNF-a, and IL-10KO DCs
produced more IFN-g and IL-12, than WT C57Bl/6 cells
(Figure 6a). DCs’ production of TNF-a was similar in
both mouse lineages. Unstimulated DCs from C57Bl/6
and IL-10KO mice showed the same level of markers
expression (Figure 6b). In contrast, IL-10KO-activated
DCs significantly upregulated the expression of CD80 and
CD40, whereas the expression of MHC II and CD86 was
only slightly upregulated at the cell surface (Figure 6c).
The murine melanoma B16F10 is considered a tumor
with low immunogenicity. These results, however, showed
that in the absence of IL-10, DCs and macrophages were
strongly stimulated by IFN-g and melanoma antigens,
Figure 4 Cloning and expression of the soluble extracellular domain of murine IL-10 receptor. (a) Positive and negative values represent
hydrophilic and hydrophobic regions of the murine IL-10 receptor, respectively, and the selected sequence indicates the region used for cloning
the sIL-10R fragment. The amino-acid residue numbers in the protein from the N-terminus (N) to the C-terminus (c) are indicated. (b) B16F10-
Nex2 cells were transfected with pcDNA3 plasmid (Cr) or with pcDNA3-sIL-10R plasmid (Tr). The mRNA of the extracellular region of IL-10
receptor (sIL-10R, 560bp) and b-actin (900bp) were detected by RT-PCR using specific primers. ST, molecular weight standard. (c) B16F10-
Nex2 cells were transfected with pcDNA3 (black) or with pcDNA3-sIL-10R (empty peak), intracellularly stained with anti-murine IL-10R
monoclonal antibody and analyzed by flow cytometry. (d) Supernatants from pcDNA3-transfected (Cr) and pcDNA3-sIL10-transfected (Tr)
B16F10-Nex2 cells were immunoprecipitated and immunodetected using anti-murine IL-10R mAb. These results are representative of at least
three independent experiments.
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suggesting that these cells were more effective in antigen
presentation, thus inducing a stronger antimelanoma-
protective response.
As DCs from IL-10KO mice showed an activated
phenotype after stimulation with melanoma antigens, we
tested the ability of these cells to induce a tumor-
protective response in vivo. Bone marrow-derived DCs,
obtained from C57Bl/6 or IL-10KO mice, were associated
with B16F10-Nex2 cell lysate and adoptively transferred
subcutaneously to C57Bl/6 animals previously to tumor
challenge. Animals vaccinated with DCs from C57Bl/6
mice were not protected against tumor development, even
in association with tumor-specific antigens. In contrast,
animals vaccinated with tumor antigen-primed DCs from
IL-10KO mice were strongly protected against melanoma
development (Figures 7a and b). Interestingly, the pro-
tection has proved to be antigen-dependent, as adoptive
transfer of IL-10KO DCs in the absence of tumor cell
lysate did not show any statistical difference from the
groups vaccinated with WT DCs (Figure 7a).
Finally, pcDNA3-sIL10R-transfected DCs from
C57Bl/6 mice were associated with tumor antigens, and
used for C57Bl/6 mice vaccination. Treatment with IL-10-
neutralized WT DCs increased significantly the survival
of tumor cell-challenged animals (Figure 7c).
Our results suggest that when IL-10 is neutralized by a
soluble decoy receptor in vivo, DCs induce a protective
antimelanoma response mainly because these cells are more
effective as antigen-presenting cells in this condition.
Discussion
The natural history of melanoma suggests that this tumor
can be recognized by the immune system. It has been
frequently observed that, at the time of clinical detection,
the primary cutaneous melanoma may exhibit histological
regression,29 and that in up to 5% patients with
metastatic disease, no obvious primary lesion is identified,
suggesting that the primary lesion had been completely
eradicated by the immune system.30,31
The role of cytokines in tumor surveillance and vaccine-
induced protective antitumor response has been sug-
gested. Murine knockout models showed that animals
deficient in the expression of IFN-g, type I or type II IFN
receptors, or some of their downstream signal-transduc-
tion intermediates have a higher frequency of tumors
compared with WT mice.8,32–34
Protective responses generated by several specific
tumor vaccines depended on a Th1-type immunity that
promotes CTL responses.35 It has been noted, however,
that single administration of proinflammatory cytokines
is not sufficient to cause tumor regression, most likely
owing to the recently well-characterized immunosuppres-
sive tumor microenvironment,36 and the observation that
after specific vaccination, progressive disease is associated
with antitumor Th2-type T-cell responses.37
To date, only IFN-a and IL-2 have been accepted by
the US Food and Drug Administration (FDA) for
Figure 5 Gene therapy with pcDNA3-sIL-10R and/or pIL-12. (a)
Survival plots for C57Bl/6 (WT) and IL-10KO mice inoculated
subcutaneously with 104 B16F10-Nex2 cells and treated with
pcDNA3 or pcDNA3-sIL-10R. Results represent two independent
experiments combined, total of 13 animals in the WT/pcDNA3 group,
16 in WT/pcDNA3-sIL-10R group, 11 in WT/PBS and 14 in the
IL-10KO/PBS group, Po0.0005, significant differences for plasmid-
treated groups. (b) C57Bl/6 mice were inoculated with tumor cells,
treated with pcDNA3-sIL-10R, and IFN-g was depleted (pcDNA3-sIL-
10R/anti-IFN-g) or not (pcDNA3-sIL-10R). Representative results of
three independent experiments, with five animals per group,
Po0.01. (c) Percentage of tumor-free C57Bl/6 mice treated with
associations of: (1) pcDNA3 and pCMV (control plasmids); (2) pCMV
control and pcDNA3-sIL-10R; (3) pcDNA3 control and pIL-12; or (4)
pcDNA3-sIL-10R and pIL-12 plasmids. Representative results of two
independent experiments, five animals per group. Po0.01, compar-
ing pcDNA3-sIL-10Rþ pCMV, pcDNA3þ pIL-12 or pcDNA3-
sIL10RþpIL-12 with pcDNA3þ pCMV groups.
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melanoma treatment. The tumor shows a poor response
to cytotoxic chemotherapy, but is sensitive to immu-
notherapy,38 which is a promising perspective.
The immunosuppressive status established during
tumor development is common to different tumor types
and its reversion has been attempted by inducing a
proinflammatory response, as by therapeutic vaccination
and/or administration of cytokines.35 In fact, it has been
recently shown that neutralization of immunosuppressive
cytokines was beneficial for the treatment of cancer.
Important immunosuppressive cytokines under investiga-
tion are IL-13, TGF-b and IL-10.
Hebeler-Barbosa et al.24 showed that IL-13 neutraliza-
tion in a biochemotherapeutic protocol reduced signifi-
cantly the development of B16F10-Nex2 melanoma, with
30% tumor-free animals. This protocol was based on the
vaccination of mice with a plasmid expressing IL-12,
associated with a cyclopalladated drug and a second
eukaryotic plasmid expressing a chimera formed by the
high-affinity a2-chain of IL-13 receptor coupled with
the Fc portion of murine immunoglobulin G2a mAb
(IL-13Ra2/Fc), as a soluble decoy receptor of the IL.
Other group used the same soluble decoy receptor for
tumor treatment with similar results.39–41 Neutralization
of TGF-b by monoclonal antibodies, antisense DNA and
recombinant eukaryotic vector expressing the extracellu-
lar portion of the TGF-b type II receptor/Fc chimera
reduced tumor development and increased survival in
several experimental tumor models.42–45
In vivo blocking of IL-10R by monoclonal antibodies
stimulated protective responses able to eliminate infec-
tious microorganisms, such as Leishmania and hepatitis C
virus,25–27 and also increased protection induced by CpG
vaccination in melanoma and colon carcinoma experi-
mental models.46
In our experiments with murine melanoma B16F10-
Nex2 cells syngeneic in C57Bl/6 mice, inhibition of tumor
development was observed in animals after subcutaneous
tumor cell challenge, producing twofold or higher IFN-g/
IL-10 ratios in splenocytes and serum. Splenocytes from
tumor-developing animals formed, in contrast, an inverse
cytokine ratio with predominant IL-10 and low IFN-g.
IL-6, an inflammatory cytokine, implicated in Th2-
polarized immune responses47,48 also had increased levels
Figure 6 Proinflammatory cytokine levels and surface activation markers on IL-10KO and C57Bl/6 antigen-presenting cells after in vitro
stimulation with IFN-g and tumor antigens. (a) Bone marrow-derived DCs and macrophages from IL-10KO or C57Bl/6 mice were stimulated for
72 h with IFN-g and B16F10-Nex2 cell lysate, and cytokine levels were measured on culture supernatants by ELISA. *Po0.05, comparing DCs
from IL-10KO and WT animals. Bone marrow-derived DCs were activated (c) or not (b) for 24 h with IFN-g and B16F10-Nex2 cell lysate, and the
expression of activation surface markers was analyzed by flow cytometry. Cells were obtained from C57Bl/6 mice (black histograms) or from
IL-10KO mice (thick lines). Non-stained mixed C57Bl/6 and IL-10KO DCs were used as a control (thin lines). Results are representative of at
least three independent experiments.
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in tumor-bearing mice. Although it has been shown that
tumor-bearing individuals have increased levels of IL-4 in
the serum,49 in our model, ex vivo tumor-stimulated
splenocytes produced similar levels of this cytokine in
tumor-bearing or tumor-resistant animals.
The association of high IL-10 and tumor development
was further analyzed using IL-10KO mice, which showed
increased survival and an IFN-g-dependent protective
response.
As IL-10 seemed to be a key immunosuppressive
cytokine in the melanoma model, we hypothesized that
IL-10 neutralization in vivo would also have an inhibitory
effect in tumor evolution. To address this possibility, a
recombinant eukaryotic plasmid expressing the soluble
extracellular region of the murine IL-10R a-chain, or
IL-10R1 chain, was constructed.
ILs can be neutralized in vivo by using mAbs, RNA
interference or plasmids expressing soluble receptors.
Owing to the safe administration, stable expression and
low price of DNA vaccines, their use is preferred to that
of repeated administrations of neutralizing antibodies or
soluble recombinant proteins. Moreover, as this kind of
treatment does not require determination of MHC alleles
of patients, and is independent of tumor antigen admin-
istration, such strategy seems to be adequate for human
cancer therapy.
It has been recently shown that the recombinant soluble
extracellular portion of human IL-10R was able to inhibit
the binding of IL-10 to the full-length receptor, and
also to antagonize biological effects of IL-10.28,50,51
The IL-10R1 chain binds to IL-10 with high affinity and
recombinant IL-10R1 exhibited antagonistic activity in
vitro.52 The extracellular region of murine IL-10R1 chain
was cloned in a pcDNA3 eukaryotic vector (pcDNA3-sIL-
10R), and the transfected cells expressed the protein,
detected intracellularly and in the culture supernatant.
Gene therapy of mice with this plasmid extended the
survival of C57Bl/6 mice inoculated subcutaneously with
B16F10-Nex2 cells. The protective response induced by
pcDNA3-sIL10R treatment was IFN-g dependent, sug-
gesting that the secreted protein acted as a decoy receptor,
inhibiting the activity of the IL-10 cytokine in vivo.
Interestingly, when animals were concomitantly treated
with a plasmid expressing murine IL-12, a stronger
protection was induced, with 80% of mice being tumor
free after 50 days, thus suggesting that the association of
proinflammatory cytokines and neutralization of IL-10
can improve tumor therapy, as previously shown with
IL-13 and TGF-b neutralization.
These results agree with previous reports that showed a
correlation between melanoma development and type-2
cytokines. Kobayashi et al.53 showed that IL-4 acceler-
ated the formation of pulmonary metastasis in the low
metastatic melanoma model with B16F1 cells. In the
subcutaneous B16F10 model, Wei et al.15 observed that
later in tumor development, there was an increased
number of CD4þ IL-10þ and NK (DX5þ ) IL-10þ cells,
and a decreased number of CD4þ IFN-gþ and NK
(DX5þ ) IFN-gþ cells. On the contrary, an increased
number of CD4þ IFN-gþ and NK (DX5þ ) IFN-gþ cells
Figure 7 Vaccination of C57Bl/6 mice with DCs in the absence of
IL-10 inhibited melanoma development in vivo. Bone marrow-derived
DCs obtained from IL-10KO or C57Bl/6 (WT) mice were stimulated
with tumor cell lysate and injected in C57Bl/6 mice previous to the
subcutaneous inoculation of (a) 5104 or (b) 104 B16F10-Nex2
cells. A group of mice in (b) and in (c) was vaccinated only with tumor
lysate, without DCs (lysate). Po0.03, comparing the group that
received IL-10KO DCsþ tumor lysate with that of WT DCsþ tumor
lysate. Results are representative of two independent experiments,
three mice per group and five animals in the lysate group. (c) WT
bone marrow-derived DCs were transfected with pcDNA3 or
pcDNA3-sIL-10R, selected with G418 and primed with B16F10-
Nex2 lysate. Mice were treated with these cells and challenged
subcutaneously with 5 104 viable B16F10-Nex2 cells. Po0.025,
comparing transfected DC groups. Results are representative of two
independent experiments, five animals per group.
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was observed early in tumor development, suggesting that
increased levels of IL-10 are associated with tumor
growth.
The therapeutic potential of IL-10 neutralization was
further supported by Terai et al.,54 who constructed a
plasmid vector expressing the extracellular domain of the
human IL-10R1/immunogobulin G1 Fc fusion protein,
called immunoadhesin. Human melanoma cells trans-
fected with this vector expressed the immunoadhesin
in vitro, which efficiently captured and neutralized the
biological activity of the exogenously added IL-10 or
endogenously produced cytokine by human tumor cells.
Tumor-specific adaptive immune responses are induced
by the activation of DCs, the professional antigen-
presenting cells, which capture tumor antigens and
present them to naı¨ve T lymphocytes. DC-based immu-
notherapy in cancer aims at promoting specific immunity
in the tumor-bearing host, and in this endeavor, DCs are
not only antigen-presenting cells, but also act as a ‘natural
adjuvant’ to boost vaccination.55–57 In the presence,
however, of immunosuppressive cytokines, tumor antigen
cross-presentation by DCs may induce T-cell anergy or
deletion. Regulatory T cells may also be stimulated
instead of an antitumor protective immune response. It
appears then that a single immunotherapeutic approach is
not effective against established tumors.58
It has been shown that DCs isolated from IL-10KO
mice have an enhanced ability to process and present
bacterial antigens inducing a rapid and robust Th1-type
T-cell response.59,60 DCs from IL-10KO mice when
stimulated by hepatocellular carcinoma antigens ex vivo
expressed enhanced levels of MHC II molecules (but not
other activation markers, CD80, CD86 or CD40) and
secreted increased amounts of IFN-g, IL-12 and TNF-a,
when compared with DCs from C57Bl/6 WT mice. These
tumor antigen-primed IL-10KO DCs induced a strong
protective immunity against the orthotopic and subcuta-
neous hepatocellular carcinoma in the mouse model.61
In this work, antigen-presenting cells (macrophages and
DCs) isolated from IL-10KO mice and primed ex vivo
with melanoma antigens secreted increased amounts of
Th1-type cytokines, IL-12, IFN-g and TNF-a. Differing
from the results by Chen et al,61 DCs from IL-10KO mice
stimulated with melanoma antigens showed increased
expression of activation markers, CD40 and CD80, on the
cell surface, and less of CD86 and MHC II molecules.
Such activated IL-10KO DCs were used for vaccination
of C57Bl/6 mice, and were as effective as in vivo gene
therapy with the plasmid pcDNA3-sIL10R in the
immunoprotection against B16F10-Nex2 subcutaneous
challenge.
Finally, DCs from C57Bl/6 WT mice had the endogen-
ously produced IL-10 neutralized by transfection with
pcDNA3-sIL10R plasmid. The transfected cells were ex
vivo primed with melanoma antigens and used for C57Bl/6
mice vaccination. Vaccinated animals, even in the absence
of an exogenous factor to induce a Th1-type immune
response, showed a significantly increased survival.
Demonstration of the tumor-promoting effect of an
immunosuppressive cytokine does not necessarily point to
the most adequate protocol to reverse this effect in WT-
susceptible animals or humans. In this work, we clearly
identified IL-10 as a key cytokine associated with tumor
development and successfully protected tumor-challenged
animals by using an IL-10 ligand and by stimulating a
Th1-type response, both actions carried out by gene
therapy.
We hypothesize that in mice treated with pcDNA3-sIL-
10R plasmid, DCs capture melanoma antigens in the
tumor microenvironment and, as IL-10 is blocked by
plasmid transfection and expression of the decoy receptor,
these cells are more effectively activated in their way to
lymph nodes, and induce a strong Th1-type immune
response. The presence of IL-12 further enhances the
Th1-protective antimelanoma response.
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